Drug Interaction Report

Maraviroc and Enzalutamide: Interaction Details

A pharmacist-reviewed analysis of the Maraviroc and Enzalutamide interaction: the documented clinical effects, severity rating, onset, mechanism, and management considerations, with cited references throughout.

AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Enzalutamide

Xtandi
+

Maraviroc

Selzentry Selzentry®
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Dr. Brian Staiger, PharmD, BCPS
Updated Aug 8, 2026
Editorial policy · Data sources
LinkedIn
Interaction severity
Major
Potentially serious — often needs a change or close monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 94 documented Maraviroc interactions, 72 are rated major — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
Onset
unspecified
Evidence
probable
Severity
Major

What happens

Reduced maraviroc exposure

Interaction Deep Dive

Concurrent use of maraviroc (a CYP3A substrate) with CYP3A inducers may reduce maraviroc exposure. When maraviroc was coadministered with rifAMPin, the maraviroc AUC decreased 63%. The concomitant use of maraviroc with a strong CYP3A inducer is contraindicated in adult and pediatric patients with CrCl less than 30 mL/min and in those with ESRD on regular hemodialysis. In adults with CrCl 30 mL/min or greater treated with maraviroc and a concurrent strong CYP3A inducer (and no strong CYP3A inhibitors), increase the maraviroc dose to 600 mg orally twice daily. In pediatric patients with CrCl 30 mL/min or greater, concomitant use of maraviroc and strong CYP3A inducers is not recommended1.

Why it happens (mechanism)

Induction of CYP3A-mediated metabolism of maraviroc

Literature reports

1 report — tap to read

a) Concomitant administration of maraviroc and rifAMPin, a strong CYP3A inducer, resulted in decreased maraviroc AUC and plasma concentrations. When rifAMPin 600 mg once daily was administered concurrently with maraviroc 100 mg twice daily in 12 patients, the ratio of maraviroc pharmacokinetic parameters with rifAMPin to without rifAMPin was: Cmin 0.22 (90% confidence interval (CI), 0.17 to 0.28), AUC 0.37 (90% CI, 0.33 to 0.41), and Cmax 0.34 (90% CI, 0.26 to 0.43) 1.

Common questions

Can I take Maraviroc and Enzalutamide together?

Reduced maraviroc exposure Always confirm with your pharmacist or prescriber before making any change.

How serious is the Maraviroc and Enzalutamide interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "probable". Good supporting evidence, though not definitively proven.

Questions for your pharmacist

  • Does my dose of Maraviroc or Enzalutamide need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (1)

  1. Product Information: SELZENTRY(R) oral tablets, oral solution, maraviroc oral tablets, oral solution. Viiv Healthcare (per manufacturer), Research Triangle Park, NC, 2016. DailyMed
Was this write-up helpful?
Enzalutamide

Keep reading about Enzalutamide

All Enzalutamide interactions (120)
Also serious with: Colchicine Lenacapavir Oral Doravirine Lurasidone
Maraviroc

Keep reading about Maraviroc

All Maraviroc interactions (94) Maraviroc drug information
Also serious with: Darunavir Atazanavir Delavirdine Conivaptan
Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

Enzalutamide + Activated Charcoal Alkanna Alpine Ragwort Black Tea Boneset Borage Butterbur Cannabidiol (cbd) + 41 more
Maraviroc + Activated Charcoal Beer Grapefruit Siberian Cocklebur St. John's Wort Wine Acacia Rigidula Adrafinil + 160 more

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.